Monday, July 27, 2026

Daily Docket: J&J Announces $5.5B Talc Agreement Covering About 76,000 Claims

These event summaries are AI-generated and still in beta. Pending our full analytics build-out, please verify critical dates independently. Spot something off? Let us know.

We tracked 81 new filings yesterday. Johnson & Johnson supplied the day’s marquee development, announcing an estimated $5.5 billion agreement covering about 76,000 existing ovarian-cancer claims involving its talc products.

The Talcum Powder Products Liability Litigation (2738) added four filings, split evenly between DV Injury Law and Levin Papantonio. Reuters reported on July 27 that Johnson & Johnson agreed to pay an estimated $5.5 billion to resolve about 76,000 existing ovarian-cancer claims consolidated in federal court in New Jersey and pending in state courts. The agreement requires acceptance by 95% of participating state and federal ovarian-cancer claimants before becoming final. It does not resolve future claims. Johnson & Johnson continues to deny that its talc products caused cancer.

The AFFF Products Liability Litigation (2873) led the day with 18 filings, equal to 8.5% of its 212 filings over the trailing 30 days. Krentsel & Guzman LLP filed 15; Culpepper & Associates and the Law Office of Barrett Yarbrough LLC appeared together on the remaining three.

The Uber Passenger Sexual Assault Litigation (3084) added 16 cases, led by Cutter Law PC with 11 and Chaffin Luhana LLP with two. The Hair Relaxer Products Liability Litigation (3060) added nine, including three from Singleton Schreiber LLP and two from Keller Postman LLC.

The Depo-Provera Products Liability Litigation (3140) added eight filings, including four from Stark & Stark PC and two jointly associated with Messerli Kramer and Storms Dworak LLC. A July 14 defense motion asked Judge M. Casey Rodgers to replace five existing pilot cases—which defendants said were eligible for a settlement program—with Yeager, Davis and Ponder, which defendants said were outside the program, and to authorize 45 days of limitations-focused discovery. Ponder did not oppose substitution in a response filed July 22 but asked the court to defer the limitations proceedings. The July 27 minute entry confirms the conference occurred but does not disclose the court’s disposition.

See the full filing feed and firm-level breakdowns here.

MASLD Review Adds Clinical Context for Ultra-Processed Food Claims

On July 25, 2026, Non-pharmacological treatment of MASLD added current clinical context to Ultra Processed Food claims by examining non-drug management of metabolic dysfunction-associated steatotic liver disease. The publication centers sustained lifestyle intervention, including dietary change, physical activity, weight reduction, and management of cardiometabolic risk factors. Its discussion of limiting ultra-processed foods situates the topic within a broader clinical treatment framework rather than a product-specific injury finding. The review does not identify a challenged product, establish defect or causation, or resolve any individual claim, but it gives counsel a fresh source for separating clinical dietary guidance from litigation-grade proof of injury.

Depression-Assessment Study Marks New Social Media Evidence Context

On July 24, 2026, Improving clinical reliability of LLM reasoning for depression assessment via structured generation and GRPO supplied a current research marker for Social Media (3047). The study examines whether structured generation and Group Relative Policy Optimization can improve the clinical reliability of large-language-model reasoning in depression assessment. It does not resolve platform liability, link any platform to a discrete injury, or establish causation for a claimant in the litigation. Its significance lies in sharpening the reliability questions counsel may confront when mental-health assessment methods, model outputs, and clinical expert evidence intersect.